abstract background: the aim of this study was to compare the effects of the second- and third-generation oral contraceptives on women’s reproductive sexual function. materials and methods: this randomized, double-blind, placebo-controlled clinical trial was conducted on 82 married women of reproductive age in tehran. samples were randomized into the groups receiving second- and third-generatio...

Public Citizen, representing more than 100,000 consumers nationwide, hereby petitlons the Food and Drug Administration (FDA) pursuant to the Federal Food, Drug and Cosmetic Act 21 U.S.C. Section 355(e)(3), and 2 1 C.F.R. 10.30, to immediately ban the third generation oral contraceptives containing desogestrel due to the approximately doubled risk of venous thrombosis (30 cases for every 100,000...

BACKGROUND AND PURPOSE Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives. METHODS A multicenter, population-based, case-control study was performed in 9 Dutch cent...

The higher risk of venous thromboembolism with 3rd and 4th- generations combined oral contraceptives compared to 2nd generation triggered a media crisis in France. Exposure to 3rd or 4th-generation combined oral contraceptives led to an annual excess of around 100 premature deaths in Europe. In the absence of any demonstrated additional benefit of these combined oral contraceptives, measures we...

Epidemiological studies indicate that use of third generation oral contraceptives increases the risk of venous thromboembolism more than does use of second generation oral contraceptives. Critics have suggested that this finding may be confounded by indication, since third generation pills were considered to be safer and were therefore perhaps prescribed more often to women at high risk. If con...

PURPOSE To estimate the number of venous thromboembolic events and related-premature mortality (including immediate in-hospital lethality) attributable to the use of combined oral contraceptives in women aged 15 to 49 years-old between 2000 and 2011 in France. METHODS French data on sales of combined oral contraceptives and on contraception behaviours from two national surveys conducted in 20...

OBJECTIVE To evaluate quantitatively articles that compared effects of second and third generation oral contraceptives on risk of venous thrombosis. DESIGN Meta-analysis. STUDIES Cohort and case-control studies assessing risk of venous thromboembolism among women using oral contraceptives before October 1995. MAIN OUTCOME MEASURES Pooled adjusted odds ratios calculated by a general varian...